STAAR SURGICAL CO STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or "refractive" surgery. We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction. Unless the context indicates otherwise, "we," "us," the "Company," and "STAAR" refer to STAAR Surgical Company and its consolidated subsidiaries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $239.4M | $313.9M | $322.4M | $239.4M | $230.5M | $163.5M | $150.2M | $22.9M | $22.3M | $23.3M |
| Cost of revenue | $57.0M | $74.3M | $69.8M | $61.0M | $51.8M | $45.1M | $38.2M | $32.4M | $26.3M | $24.1M |
| Gross profit | $182.4M | $239.6M | $252.7M | $223.4M | $178.6M | $118.4M | $112.0M | $91.5M | $64.3M | $58.4M |
| R&D | $40.1M | $45.3M | $40.5M | $36.0M | $33.9M | $31.9M | $25.3M | $22.0M | $20.0M | $20.7M |
| SG&A | $274.1M | $252.2M | $224.6M | $179.6M | $145.3M | $111.6M | $100.1M | $84.9M | $67.9M | $71.0M |
| Operating income | -$91.7M | -$12.6M | $28.1M | $43.8M | $33.3M | $6.8M | $11.9M | $6.6M | -$3.6M | -$12.7M |
| Interest expense | — | — | — | — | — | — | — | — | $112.0K | $112.0K |
| Pre-tax income | -$82.3M | -$9.1M | $33.7M | $45.6M | $31.3M | $8.3M | $13.0M | $6.6M | -$2.3M | -$12.4M |
| Income tax | $1.8M | $11.2M | $12.3M | $5.9M | $3.8M | $2.4M | $1.0M | $1.7M | $157.0K | $315.0K |
| Net income | -$80.4M | -$20.2M | $21.3M | $39.7M | $27.5M | $5.9M | $14.0M | $5.0M | -$2.1M | -$12.1M |
| EPS, basic | -1.62 | -0.41 | 0.44 | 0.83 | 0.58 | 0.13 | 0.32 | 0.12 | -0.05 | -0.30 |
| EPS, diluted | -1.62 | -0.41 | 0.43 | 0.80 | 0.56 | 0.12 | 0.30 | 0.11 | -0.05 | -0.30 |
| Shares, diluted (wtd. avg.) | $49.6M | $49.1M | $49.4M | $49.4M | $49.5M | $48.0M | $46.9M | $45.3M | $41.0M | $40.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $153.2M | $144.2M | $183.0M | $86.5M | $199.7M | $152.5M | $120.0M | $104.0M | $18.6M | $14.1M |
| Short-term investments | $34.4M | $86.3M | $37.7M | $125.2M | — | — | — | — | — | — |
| Receivables | $50.1M | $77.9M | $94.7M | $62.4M | $43.5M | $35.2M | $31.0M | $25.9M | $17.9M | $16.3M |
| Total current assets | $311.5M | $367.9M | $365.3M | $311.7M | $271.4M | $216.4M | $174.7M | $151.6M | $53.9M | $49.5M |
| Property, plant and equipment | $73.3M | $84.9M | $66.8M | $50.9M | $35.9M | $24.0M | $17.1M | $11.5M | $9.8M | $11.8M |
| Goodwill | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M | $1.8M |
| Other intangibles | — | — | — | $173.0K | $218.0K | $270.0K | $296.0K | $243.0K | $271.0K | $473.0K |
| Total assets | $451.7M | $509.5M | $488.7M | $418.8M | $345.8M | $257.4M | $207.5M | $167.3M | $67.9M | $65.5M |
| Accounts payable | $11.6M | $16.7M | $13.6M | $11.6M | $8.7M | $7.5M | $8.1M | $6.5M | $6.0M | $8.3M |
| Total current liabilities | $68.5M | $70.3M | $65.0M | $51.7M | $48.8M | $41.2M | $34.5M | $27.7M | $19.1M | $21.1M |
| Total liabilities | $107.5M | $112.2M | $102.7M | $82.7M | $87.2M | $60.2M | $47.6M | $34.9M | $25.0M | $27.6M |
| Retained earnings | -$148.0M | -$67.6M | -$47.4M | -$68.7M | -$111.4M | -$135.9M | -$141.8M | -$156.3M | -$161.2M | -$159.1M |
| Total equity | $344.2M | $397.3M | $386.0M | $336.1M | $261.6M | $197.2M | $159.9M | $132.4M | $42.9M | $37.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.2M | $15.7M | $14.6M | $35.7M | $44.0M | $21.0M | $25.8M | $12.8M | $2.9M | $1.0M |
| Depreciation and amortisation | $8.3M | $6.9M | $5.1M | $4.5M | $3.6M | $3.1M | $3.7M | $2.4M | $3.1M | $2.7M |
| Stock-based compensation | $30.6M | $27.2M | $23.5M | $20.4M | $14.6M | $12.1M | $10.5M | $6.8M | $3.2M | $8.6M |
| Capital expenditure | $5.8M | $23.4M | $18.2M | $18.1M | $13.6M | $8.4M | $10.1M | $2.2M | $1.0M | $3.2M |
| Investing cash flow | $46.3M | -$59.2M | $74.3M | -$156.4M | -$13.6M | -$8.4M | -$10.2M | -$2.2M | -$1.0M | -$3.2M |
| Financing cash flow | -$4.6M | $5.7M | $7.4M | $8.3M | $17.8M | $19.6M | $149.0K | $74.6M | $2.4M | $3.0M |
| Buybacks | $6.5M | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000718937-26-000015.
Others in SIC 3851
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| COO | COOPER COMPANIES, INC. | $13.57B | 37.2x | 5.1% |
| BLCO | Bausch & Lomb Corp | $6.44B | — | 6.5% |
| WRBY | Warby Parker Inc. | $3.02B | 2,435.0x | 13.0% |
| EYE | National Vision Holdings, Inc. | $1.32B | 45.2x | 9.0% |
| RXST | RxSight, Inc. | $265.2M | — | -3.9% |
| LUCYW | Innovative Eyewear Inc | $275.5K | — | 62.6% |
| ALC | ALCON INC | — | — | 4.9% |